Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Completed · Phase 3

Conditions studied: Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

In brief

Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.

Key facts

Study ID

NCT00168740

Run by

Biogen

People needed

150

Starts

1995-04-01

Last updated by the study team

2005-09-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of relapsed, low-grade or follicular B-cell lymphoma
• CD20-positive lymphoma
• Progressive, measurable disease
• Sign informed consent
• 3 weeks beyond standard therapy
• Good performance status
• Adequate hematologic, renal, and hepatic function

You may not qualify if…

• Chronic lymphocytic leukemia
• Lesions greater than or equal to 10 cm in diameter
• CNS lymphoma
• AIDS-related lymphoma
• Pleural effusions or ascites secondary to lymphoma
• Active, opportunistic infection
• Serious nonmalignant disease
• Prior investigational therapies, including prior anti-CD20 therapy
• Recent major surgery

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• City of Hope Natioal Medical Center — Duarte, California, United States
• Scripps Memorial Hospital — La Jolla, California, United States
• UCSD Stem Cell Laboratory — La Jolla, California, United States
• Hoag Hospital — Newport Beach, California, United States
• Sutter Cancer Center — Sacramento, California, United States
• Sidney Kimmel Cancer Center — San Diego, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Stanford University Medical Center — Stanford, California, United States
• Kaiser Permanente Medical Center — Vallejo, California, United States
• Rocky Mountain Cancer Center — Denver, Colorado, United States
• Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Robert H. Lurie Cancer Center, Northwestern University — Chicago, Illinois, United States
• University of Iowa General Hospital — Iowa City, Iowa, United States
• University of Kentucky Medical Center — Lexington, Kentucky, United States
• Louisiana State University — Shreveport, Louisiana, United States
• University of Maryland Cancer Center — Baltimore, Maryland, United States
• Michigan State University — East Lansing, Michigan, United States
• St. Louis University Medical Center — St Louis, Missouri, United States
• Roswell Park Cancer Center — Buffalo, New York, United States
• University of Rochester Cancer Center — Rochester, New York, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• The West Clinic, P.C. — Memphis, Tennessee, United States
• Texas Oncology, P.A. — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.